by Jordana Choucair | Oct 25, 2022 | Providers
A survey of 600 physicians found that 95 percent are interest in learning about new clinical trials and innovative treatments, but most feel overwhelmed by the amount of information. The survey also revealed that physicians want information that reflects diversity of...
by Jordana Choucair | Oct 25, 2022 | Providers
The U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) is seeking to fine Merck for cutting off 340B sales to hospitals’ contract pharmacies. Merck previously told its covered entities that they must participate in...
by Jordana Choucair | Oct 24, 2022 | Life Sciences
Pfizer plans to increase the price of its COVID-19 vaccine to between $110 to $130 per dose once the U.S. government’s purchasing program ends early next year. The price is roughly four times what the federal government pays per dose ($30). According to a Pfizer...
by Jordana Choucair | Oct 24, 2022 | Life Sciences
Peter Marks, the Food and Drug Administration’s vaccines chief, said in an interview that he’s worried about the possibility of deploying another COVID-19 booster before next September or October because of the speed at which the virus is evolving. Marks...
by Jordana Choucair | Oct 24, 2022 | M&A
Federal Trade Commission (FTC) Chair Lina Khan said the agency is “looking closely at the role of private equity” in health deals, especially when investors purchase several businesses in the same industry. Examining roll-up transactions by private equity...
Recent Comments